Nicolas Trebouta - Onxeo SA Insider

C4X -- Germany Stock  

EUR 1.09  0.003  0.28%

  Executive
Dr. Nicolas Trebouta has served as Member of the Board Permanent Representative of Financiere de la Montagne at Bioalliance Pharma SA as of June 29, 2011. Since 2004, he was via his company Financiere de la Montagne, investing in biotechnology companies, directly or through funds. He cofounded Chevrillon et Associe in 2000 and through this structure achieved several LBO such as Picard, CPI or Alingia . He was a Medical Doctor and shareholder of BioAlliance Pharma SA since 2008. Dr. Trebouta also serves as Manager of SARL Financiere de la Montagne, SCI Fleurus Immobilier and SCI du Trillon Chairman of SAS Dragon 8, and Director of GIE IO, among others.
  Executive Since 2011      
33 1 45 58 76 00  http://www.onxeo.com

Management Efficiency

The company has return on total asset (ROA) of (11.81) % which means that it has lost $11.81 on every $100 spent on asset. This is way below average. Similarly, it shows return on equity (ROE) of (82.07) % meaning that it generated substantial loss on money invested by shareholders.
The company has accumulated 130 K in total debt with debt to equity ratio (D/E) of 0.2 which may suggest the company is not taking enough advantage from borrowing. Onxeo SA has Current Ratio of 1.61 which is within standard range for the sector.

Entity Summary

Onxeo SA, a biotechnology company, develops drugs for the treatment of orphan oncology diseases worldwide. The company was formerly known as BioAlliance Pharma SA and changed its name to Onxeo SA in July 2014. Onxeo SA operates under Biotechnology classification in Germany and traded on Frankfurt Stock Exchange. It employs 43 people.Onxeo SA (C4X) is traded on Frankfurt Stock Exchange in Germany. It is located in 49, Boulevard du g?n?ral Martial Valin and employs 43 people.

Onxeo SA Leadership Team

Elisabeth Carstensen, Director of Alliance Management, Member of the Executive Committee
Russell Greig, Independent Member of the Board
Remi Droller, Member of the Board - Representative of Kurma Life Science Partners
Daniele GuyotCaparros, Independent Member of the Board
Michel Forest, Vice President Quality Qualified Person and Member of the Executive Committee
Caroline Lemarchand, Preclinical R&D Director, Member of the Executive Committee
Olivier Beaumont, Chief Medical Officer, Member of the Executive Committee
Aude Michel, Director of Legal Affairs, Agreements and Licensing, Member of the Executive Committee
Sonia Vallons, Quality Assurance Director, Member of the Executive Committee
Thomas Hofstaetter, Independent Member of the Board
Delphine Lucas, Regulatory Affairs Director, Member of the Executive Committee
Patrick Langlois, Independent Chairman of the Board
Graham Dixon, Chief Scientific Officer, Head of Research & Development, Member of the Executive Committee
Francoise Bono, Chief Scientific Officer, Member of the Executive Committee
Nicolas Trebouta, Member of the Board - Permanent Representative of Financiere de la Montagne
Audrey LegentilDumery, Director of Human Resources, Member of the Executive Committee
Judith Greciet, CEO, Member of the Executive Committee, Member of the Board
Nicolas Fellman, Vice President CFO, Member of the Executive Committee
David Solomon, Independent Member of the Board
Joseph Zakrzewski, Non-Executive Chairman of the Board
Louis Kayitalire, Vice President Head of Research & Development
Philippe Maitre, Executive Vice President and Chief of U.S. Operations

Stock Performance Indicators

Current Sentiment - C4X

Onxeo SA Investor Sentiment

Macroaxis portfolio users are unresponsive in their opinion about investing in Onxeo SA. What is your perspective on investing in Onxeo SA? Are you bullish or bearish?
Bullish
Bearish
50% Bullish
50% Bearish
Skip

Onxeo SA Pair Correlation

Equities Pair Trading Analysis

Correlation analysis and pair trading evaluation for Onxeo SA and Steris Plc. Pair trading can be used as a hedging technique within a particular sector or industry or even over random equities to generate better risk-adjusted return
Run Pair Correlation  
Check also Trending Equities. Please also try Content Syndication module to quickly integrate customizable finance content to your own investment portal.
Search macroaxis.com